Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2350)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4745)
  2. Department of Medicine (4743)
  3. Center for Pancreatic Cancer Research (2313)
  4. Surgery (1065)
  5. Survivorship Research (1013)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (220)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (147)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (320)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4745)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection
    Meeting Abstract

    Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
    Meeting Abstract

    André, T.; Shiu, K.; Kim, T.; Jensen, B.; Jensen, L.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Alcaide García, J.; Gibbs, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Effect of prior bevacizumab treatment in BRAF V600Emutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC
    Meeting Abstract

    Aderka, D.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Golden, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
    Meeting Abstract

    Ducreux, M.; Abou-Alfa, G.; Ren, Z.; Edeline, J.; Li, Z.; Assenat, E.; Rimassa, L.; Blanc, J.; Ross, P.; Fang, W.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
    Meeting Abstract

    Tabernero, J.; Cohen, D.; Van Cutsem, E.; Janjigian, Y.; Bang, Y.; Qin, S.; Wang, A.; Hawk, N.; Shih, C.; Bhagia, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Meeting Abstract

    Strickler, J.; Nakamura, Y.; Shitara, K.; Catenacci, D.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Lee, J.; Van Cutsem, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
    Meeting Abstract

    Siena, S.; Elez, E.; Peeters, M.; André, T.; Van den Eynde, M.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F.; Hubbard, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response
    Meeting Abstract

    Abou-Alfa, G.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.; Borad, M.; Gallinson, D.; Murphy, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data
    Meeting Abstract

    Li, C.; Ferro, A.; Mhatre, S.; Lu, D.; Lawrance, M.; Li, S.; Allen, S.; Desai, J.; Fakih, M.; Kim, T.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
    Meeting Abstract

    Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S.; Hyung, W.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save